KLRA

Kailera announced Phase 1 data for ribupatide injection at EASD.

Kailera Therapeutics (KLRA) said Wednesday that enrollment in the KaiNETIC global phase 3 clinical p

- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher - Topline data now expected in mid-2028 WALTHAM, Mass., Sept.

During the lightning round of the September 10 episode of Mad Money, a caller asked if Kailera Therapeutics, Inc. (NASDAQ:KLRA) is a buy, sell, or hold. In response, Jim Cramer said: Okay, I actually know this, but okay, here’s the problem.

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

Kailera Therapeutics (KLRA) is in focus after reporting a second quarter net loss of US$111.31 million and a six month net loss of US$190.17 million, alongside the appointment of Nur Nicholson as Chief Technology Officer.

Veteran technical operations executive to lead manufacturing and supply chain strategy as company advances late-stage obesity pipeline toward commercializationWALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc.

Kailera Therapeutics Inc. (NASDAQ:KLRA) is one of the best IPO stocks with huge upside potential.

In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global Phase 2 trial of KAI-7535 in obesity to further optimize…